Amphotericin B: side effects and toxicity

被引:515
作者
Laniado-Laborin, Rafael [1 ]
Noemi Cabrales-Vargas, Maria [1 ]
机构
[1] Univ Autonoma Baja California, Fac Med Tijuana, Mexicali 21100, Baja California, Mexico
来源
REVISTA IBEROAMERICANA DE MICOLOGIA | 2009年 / 26卷 / 04期
关键词
Amphotericin B; Adverse effects; Toxicity; INVASIVE FUNGAL-INFECTIONS; LIPID COMPLEX; HYPOKALEMIC RHABDOMYOLYSIS; COLLOIDAL DISPERSION; INFUSION; FORMULATIONS; NEPHROTOXICITY; HYPERKALEMIA; EFFICACIES;
D O I
10.1016/j.riam.2009.06.003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Amphotericin B (AmB) is a crucial agent in the management of serious systemic fungal infections. In spite of its proven track record, its well-known side effects and toxicity will sometimes require discontinuation of therapy despite a life-threatening systemic fungal infection. The mechanism of action of AmB is based on the binding of the AmB molecule to the fungal cell membrane ergosterol, producing an aggregate that creates a transmembrane channel, allowing the cytoplasmic contents to leak out, leading to cell death. Most of the efforts at improving AmB have been focused on the preparation of AmB with a lipid conjugate. AmB administration is limited by infusion-related toxicity, an effect postulated to result from proinflammatory cytokine production. The principal acute toxicity of AmB deoxycholate includes nausea, vomiting, rigors, fever, hypertension or hypotension, and hypoxia. Its principal chronic adverse effect is nephrotoxicity. AmB probably produces renal injury by a variety of mechanisms. Risk factors for AmB nephrotoxicity include male gender, higher average daily dose of AmB (>= 35 mg/day), diuretic use, body weight >= 90 kg. concomitant use of nephrotoxic drugs, and abnormal baseline renal function. Clinical manifestations of AmB nephrotoxicity include renal insufficiency, hypokalemia, hypomagnesemia, metabolic academia, and polyuria due to nephrogenic diabetes insipidus. Human studies show convincingly that sodium loading in excess of the usual dietary intake notably reduces the incidence and severity of AmB-induced nephrotoxicity. (C) 2008 Revista Iberoamericana de Micologia. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 52 条
[1]  
ALTMANNSBERGER P, 2004, J ANTIMICROB CHEMOTH, V54, P803
[2]  
ANDERSON CM, 1995, WESTERN J MED, V162, P313
[3]  
Antony S, 2003, J NATL MED ASSOC, V95, P982
[4]  
Bagnis Corinne Isnard, 2002, Saudi J Kidney Dis Transpl, V13, P481
[5]  
Barcia JP, 1998, PHARMACOTHERAPY, V18, P874
[6]   A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [J].
Barrett, JP ;
Vardulaki, KA ;
Conlon, C ;
Cooke, J ;
Daza-Ramirez, P ;
Evans, EGV ;
Hawkey, PM ;
Herbrecht, R ;
Marks, DI ;
Moraleda, JM ;
Park, GR ;
Senn, SJ ;
Viscoli, C .
CLINICAL THERAPEUTICS, 2003, 25 (05) :1295-1320
[7]   RENAL MAGNESIUM WASTING ASSOCIATED WITH AMPHOTERICIN-B THERAPY [J].
BARTON, CH ;
PAHL, M ;
VAZIRI, ND ;
CESARIO, T .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (03) :471-474
[8]   Correlates of acute renal failure in patients receiving parenteral amphotericin B [J].
Bates, DW ;
Su, L ;
Yu, DT ;
Chertow, GM ;
Seger, DL ;
Gomes, DRJ ;
Platt, R .
KIDNEY INTERNATIONAL, 2001, 60 (04) :1452-1459
[9]  
Berdichevski Roberto Herz, 2006, Braz J Infect Dis, V10, P94, DOI 10.1590/S1413-86702006000200005
[10]   Carrier effects on biological activity of amphotericin B [J].
Brajtburg, J ;
Bolard, J .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (04) :512-+